Pregnancy of Unknown Location in a Patient With a Prior Ectopic and One Remaining Tube
30-year-old G4P2 with a prior right salpingectomy for ectopic pregnancy presents with 6 weeks 5 days of amenorrhea and mild left lower quadrant pain. She is hemodynamically stable. Transvaginal ultrasound shows an empty uterus and no adnexal mass; there is no free fluid. Serum hCG is 1,650 mIU/mL and progesterone is 8 ng/mL. She strongly wants to avoid surgery because her prior ectopic surgery was traumatic, and she asks about “the shot.” She has no renal, hepatic, or hematologic disease and does not smoke.
1. How do you classify this pregnancy, and what are the next steps?
Read the worked answer
This is a pregnancy of unknown location: the hCG is above many discriminatory thresholds, but an empty uterus does not prove ectopic pregnancy, and no adnexal mass is seen. The low progesterone is suggestive of a nonviable pregnancy but is not diagnostic. The differential includes early intrauterine pregnancy, ectopic pregnancy, and resolved pregnancy of unknown location. Because she is stable with mild pain and no free fluid, immediate surgery is not mandatory, but she needs serial hCG measurements and repeat ultrasound, usually in 48 hours, with clear warning signs and a 24-hour contact plan.
Counsel her that the diagnosis may evolve. If hCG rises abnormally or she develops severe pain, syncope, or free fluid, proceed urgently. Do not give methotrexate before a diagnosis is established unless a multidisciplinary plan is in place for a persistent pregnancy of unknown location, because methotrexate is teratogenic and could expose an early intrauterine pregnancy.
2. Is she a candidate for methotrexate? What factors favor methotrexate versus surgery?
Read the worked answer
She is a potential candidate if the diagnosis becomes a presumed ectopic pregnancy: she is hemodynamically stable, has no fetal cardiac activity, hCG is below 5,000 mIU/mL, and she has no renal, hepatic, or hematologic contraindications. A mass, if later seen, should be under 4 cm. Her prior salpingectomy is not a contraindication, but it is highly relevant because she has only one tube; methotrexate may preserve that tube, whereas surgery may be definitive and could leave her without a tube.
Factors favoring methotrexate include stability, a desire to avoid surgery, and a small unruptured ectopic. Factors favoring surgery include severe pain, rupture, large mass, fetal cardiac activity, contraindications to methotrexate, inability to comply with follow-up, and patient preference for a definitive approach. She must understand that methotrexate requires prolonged hCG surveillance, avoidance of pregnancy for at least three months, and a risk of treatment failure requiring surgery. Shared decision-making should explicitly address her prior surgical trauma and future fertility goals.
3. She elects methotrexate. Day 4 hCG is 2,400 mIU/mL and day 7 is 2,100 mIU/mL. Interpret and manage.
Read the worked answer
A rise from day 1 to day 4 is expected and does not indicate failure. Success with single-dose methotrexate is defined by a decline of at least 15% from day 4 to day 7. Here the decline is 300/2,400, or 12.5%, which does not meet the threshold. She needs either a second dose of methotrexate or surgical management, depending on her stability, pain, and preferences. Before a second dose, recheck renal and hepatic function and CBC, and confirm she is not pregnant in the uterus.
Counsel her that treatment failure is not her fault and that surgery may still be needed. If she remains stable and wants another dose, give it and repeat hCG on days 4 and 7 after the second dose. If she develops severe pain, free fluid, or hemodynamic instability, proceed to surgery immediately. Continue contraception counseling and defer pregnancy for at least three months after the final dose.